tirzepatide crohn's & Disease: Safe Weight Loss The Potential for GLP-1s in

All providers advise patients to seek emergency care for serious side effects such as signs of pancreatitis, severe allergic reactions, or other emergency symptoms

The peptides were not FDA-approved

In direct trials, it notably outperformed injectable semaglutide (Ozempic)

This has led to increased interest in whether medications like Wegovy might offer additional support for weight loss in this patient population, whilst raising important questions about safety and potential interactions with thyroid function

Sometimes it is referred to as GLP-3 because it is a 3rd-generation triple agonist targeting 3 receptors, unlike Ozempic, which targets a single receptor

We guide you through: You dont have to figure this out alone